CRT-156 Two Year Safety And Clinical Performance Of The Drug Eluting Orsiro Stent In The Treatment Of Subjects With Single De Novo Coronary Artery Lesions (BIOFLOW-II)

Abstract

were diabetes (41.3%), hypertension (69.4%), hypercholesterolemia (75.7%) and history of smoking (47.6%). STEMI (3.9%) and NSTEMI (13.1%) were present at baseline. Lesion characteristics were 3.02 AE 0.64 mm (reference vessel diameter) and 14.6 AE 6.5 mm (lesion length). Treated vessels were LAD (37.6%), RCA (28.6%), LCX (27.6%) and others (6.2%). Cypher-ISR (36.7%) was the most common type of DES-ISR followed by Taxus-ISR (20.0%), Xience-ISR (20.0%), Promus-ISR (8.1%), Endeavor-ISR (5.7%) and others (9.5%). ISR patterns were focal (52.9%) and diffuse (47.1%). 9-month follow-up was available in 90.8% (187/206) of all patients. The duration between DES implantation and restenosis was 3.0 AE 2.4 years.The 9-month TLR rate was 7.0% (13/187) whereas incidences of MI and cardiac death were 4.3% (8/187) and 2.1% (4/187) respectively. The composite MACE rate at 9 months was 10.2% (19/187).CONCLUSIONS Up to date this is the largest prospective registry in an unselected patient population with DES-ISR treated with PCB angioplasty. The rates for TLR and MACE were low and seem to be an attractive alternative treatment option despite the lack of reimbursement in France.

Still room for improvement: Preclinical and bench testing of a thin‐strut cobalt–chromium bare‐metal stent with passive coating

“…35 At 2 years, the rate of target lesion failure was even numerically lower for Orsiro (8.4% vs. 10.0%; p 5 nonsignificant). 36 The study continues up to 5 years of follow-up, where long-term results, mostly depending on the underlying metallic backbone, might be linked to the observations from these preclinical studies.…”